[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100560341":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":18,"locations":24,"responsibleParty":38,"collaborators":10,"id":42,"slug":43,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":10,"eligibilityCriteria":48,"healthyVolunteers":44,"sex":49,"minAge":50,"maxAge":10,"enrollmentInfo":51,"targetDuration":54,"studyType":55,"phases":10,"briefSummary":56,"conditions":57,"keywords":10,"overallStatus":26,"whyStopped":10,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},{"fullName":5,"class":6},"Vanderbilt University Medical Center","OTHER",[8,12,15],{"label":9,"type":10,"description":11,"interventionNames":10},"TTN-positive",null,"Patients with a pathogenic or likely pathogenic variant in TTN on clinical genetic testing.",{"label":13,"type":10,"description":14,"interventionNames":10},"Gene-positive","Patients with a pathogenic or likely pathogenic variant in a gene other than TTN on clinical genetic testing.",{"label":16,"type":10,"description":17,"interventionNames":10},"Gene-negative","Patients without a pathogenic or likely pathogenic variant in a cardiomyopathy or arrhythmia gene on clinical genetic testing.",[19],{"name":20,"role":21,"phone":22,"phoneExt":10,"email":23},"Dakota Graherr, RN","CONTACT","615-936-6069","dakota.grauherr@vumc.org",[25],{"facility":5,"status":26,"city":27,"state":28,"zip":29,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":10},"RECRUITING","Nashville","Tennessee","37232","United States","US",{"type":33,"coordinates":34},"Point",[35,36],-86.78444,36.16589,{"lat":36,"lon":35},{"type":39,"investigatorFullName":40,"investigatorTitle":41,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","James L. Laws","Assistant Professor of Medicine","100560341","defining-the-risk-of-ventricular-tachycardia-in-genetic-cardiomyopathies-100560341",false,"NCT06575881","Defining the Risk of Ventricular Tachycardia in Genetic Cardiomyopathies","Defining the Risk of Ventricular Tachycardia in Genetic Forms of Early-onset Atrial Fibrillation","Inclusion Criteria:\n\n* Adults aged 18 and older\n* Diagnosed with AF, frequent PVCs, or VT before age 60\n* Scheduled for catheter-based AF ablation (de-novo or repeat) OR catheter-based PVC ablation OR catheter-based VT ablation\n* Able to provide written, informed consent\n* P\u002FLP variant in TTN or other CM gene (cases) or identified as a genotype-negative control.\n\nExclusion Criteria:\n\n* Diagnosed with a genetic CM or arrhythmia syndrome prior to ablation procedure\n* VUS in 'possibly pathogenic' subgroup (control group only)\n* Previous PVC or VT ablation\n* LVEF \\\u003C20%\n* Prosthetic mitral or aortic valve\n* Contraindication to heparin\n* Prior myocardial infarction","ALL","18 Years",{"count":52,"type":53},200,"ESTIMATED","3 Years","OBSERVATIONAL","The goal of this observational study is to determine if electrophysiologic mapping and cardiac MRI can help identify patients that have genetic forms of cardiomyopathy that are at high risk for development of dangerous ventricular arrhythmias.\n\nThe investigators aim to study:\n\n1. the prevalence and mechanism of inducible ventricular tachycardia\n2. pace-mapping to define the site of origin of ventricular arrhythmias\n3. voltage mapping to define low voltage scar substrate in the basal LV to determine the risk of development of ventricular arrhythmias in patients with genetic forms of cardiomyopathy.\n\nParticipants will undergo cardiac MRI before their scheduled procedure and voltage mapping during their scheduled procedure as part of data collection.",[58,59,60],"Atrial Fibrillation","Ventricular Tachycardia","Premature Ventricular Contraction","2026-04-30",{"date":63,"type":64},"2026-05-06","ACTUAL",{"date":66,"type":64},"2023-12-13",{"date":68,"type":53},"2029-12",{"name":5,"class":6},1]